In breast cancer cells, TG2 overexpression conferred EMT and stem-cell-like phenotypes, and IL-1β treatment increased stem-cell-like phenotypes, invasion, and estrogen-independent tumor growth in a TG2-dependent manner, which was attenuated by either anti-IL-6 or anti-IL-1β antibody treatment. The gene discussed is IL6; the disease is neoplasm.